title: Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials.
authors.affiliation: Department of Oncology, Mater Salutis Hospital, Legnago, Italy. Electronic address: giuliani.jacopo@alice.it.
authors.forename: Jacopo
authors.initials: J
authors.lastname: Giuliani
authors.affiliation: Department of Oncology, Mater Salutis Hospital, Legnago, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Bonetti
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000191:economics / Q000235:genetics; D017326:Clinical Trials, Phase III as Topic; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics; D006801:Humans; D058990:Molecular Targeted Therapy; D009154:Mutation / Q000235:genetics; D009367:Neoplasm Staging; D047428:Protein Kinase Inhibitors / Q000191:economics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
chemical_list: D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: Advanced NSCLC; Costs of drugs; First-line chemotherapy; Randomized phase III trials; Targeted therapies